• Explore /
  • Poster
  • / Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).

Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).

Abstract Poster

Authors

null

Anser Ali Abbas

Cedars-Sinai Medical Center, Los Angeles, CA

Anser Ali Abbas , John Davelaar , Jessica Gai , Zachariah Brown , Abrahm Levi , Sheila Linden , Angela Minasyan , Christina Rodriguez , Jonathan A. Pachter , Jun Gong , Brent K Larson , Andrew Eugene Hendifar , Simon Lo , Srinivas Gaddam , Kambiz Kosari , Nicholas Nissen , Stephen Jacob Pandol , Richard Burkhart , Lei Zheng , Arsen Osipov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT03727880

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4024)

DOI

10.1200/JCO.2023.41.16_suppl.4024

Abstract #

4024

Poster Bd #

346

Abstract Disclosures

Funded by Conquer Cancer

Similar Posters

First Author: John Davelaar

First Author: Benjamin Adam Weinberg

First Author: Shipra Gandhi

First Author: Benjamin Adam Weinberg